Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma
Results From the CheckMate 67T Trial
Results From the CheckMate 67T Trial
Saby George, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, shared results from the CheckMate 67T trial, comparing subcutaneous nivolumab to intravenous nivolumab among patients with previously treated advanced or metastatic clear cell renal cell carcinoma.
Subcutaneous nivolumab was found to be noninferior to intravenous nivolumab for both the primary end points of pharmacokinetics and the secondary end points of objective response rates, and there were no new safety signals observed. Dr George also highlighted the difference in time of administration between the arms, with subcutaneous nivolumab requiring a 5 minutes or less, while intravenous administration required a median of 30 minutes.
Source:
George S, Bourlon MT, Chacon MR, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. Presented at the 2024 ASCO Genitourinary Cancers Symposium; January 25-27, 2024; San Francisco, California. Abstract LBA360
